FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 119 filers reported holding FATE THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $2,964,000 | -81.5% | 50,000 | -73.0% | 0.87% | -80.4% |
Q2 2021 | $16,056,000 | +5.3% | 185,000 | 0.0% | 4.41% | +23.1% |
Q1 2021 | $15,253,000 | +1.7% | 185,000 | +12.1% | 3.58% | +7.2% |
Q4 2020 | $15,003,000 | +87.7% | 165,000 | -17.5% | 3.34% | +44.7% |
Q3 2020 | $7,994,000 | +86.4% | 200,000 | +60.0% | 2.31% | +104.1% |
Q2 2020 | $4,289,000 | -14.2% | 125,000 | -44.4% | 1.13% | -14.6% |
Q1 2020 | $4,997,000 | -7.2% | 225,000 | -18.2% | 1.32% | +29.3% |
Q4 2019 | $5,382,000 | -1.0% | 275,000 | -21.4% | 1.02% | -26.0% |
Q3 2019 | $5,436,000 | +344.8% | 350,000 | +366.7% | 1.38% | +432.7% |
Q3 2018 | $1,222,000 | +156.7% | 75,000 | -15.9% | 0.26% | +21.5% |
Q3 2015 | $476,000 | – | 89,231 | – | 0.21% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |